AI Article Synopsis

  • PTEN loss is associated with poor outcomes in various tumors, and the study aims to better understand the role of a longer PTEN variant (PTEN-L) in tumor progression and cell dormancy.
  • Researchers used CRISPR/Cas9 to create PTEN knockout cell lines and evaluated tumor metastasis in mouse models, employing several biochemical techniques to investigate the underlying mechanisms.
  • The findings indicate that PTEN-L protects PTEN-deficient tumor cells from chemotherapy-induced death by inducing dormancy and activating the p38 signaling pathway, suggesting that PTEN-L could influence tumor cell behavior and treatment responses.

Article Abstract

Background: PTEN loss has been identified in various tumor types and is linked to unfavorable clinical outcomes. In addition to PTEN mutation, multiple mechanisms contribute to PTEN loss during tumor development. However, the natural selection process of PTEN-deficient tumor cells remains unclear. Here, we aimed at further elucidating the role of PTEN-L in tumor progression.

Methods: PTEN knockout cell lines were generated using CRISPR/Cas9 technology. Ni-NTA affinity column chromatography was employed for PTEN-L purification. Tumor cell metastasis was evaluated in murine models and observed using the IVIS Spectrum Imaging System. RNA-sequencing, western blotting, PCR, flow cytometry, and cell proliferation assays were employed to investigate tumor cell dormancy and related mechanisms.

Results: The chemotherapeutic drugs, cisplatin, paclitaxel, and doxorubicin, induced tumor cells to secrete PTEN-long (PTEN-L), which shields PTEN-deficient tumor cells from chemotherapy-induced apoptosis better than it shields PTEN-intact cells. Further investigation revealed that PTEN-L treatment induced dormancy in PTEN-null tumor cells, characterized by an increase in p16 and p27 levels, cell-cycle arrest, reduced cell proliferation, and enhanced DNA repair. Furthermore, PTEN-L treatment selectively promoted the accumulation and growth of PTEN-null tumor cells in the lungs of C57BL/6J mice, while evading immune surveillance. Mechanistically, PTEN-L induced dormancy in PTEN-null tumor cells by activating the p38 signaling pathway. Addition of a p38 inhibitor effectively reversed dormancy and growth of PTEN-deficient tumor cells in the lungs. We also demonstrated that PTEN expression played a pivotal role in determining the outcome of PTEN-L-mediated antitumor therapy.

Conclusions: In summary, PTEN-L was identified as a potent inducer of dormancy in PTEN-deficient tumor cells, which increased their efficient selection within the tumor microenvironment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11088029PMC
http://dx.doi.org/10.1186/s13046-024-03059-yDOI Listing

Publication Analysis

Top Keywords

tumor cells
36
pten-deficient tumor
20
tumor
15
pten-null tumor
12
cells
10
pten loss
8
tumor cell
8
cell proliferation
8
pten-l treatment
8
induced dormancy
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!